why choose us

First received: August 24, 2022

Clinical Trial: Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Study Type: Expanded Access


Brief Summary: To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.

Read more